Portolan Capital Management LLC Sells 12,687 Shares of United Therapeutics Corporation $UTHR

Portolan Capital Management LLC cut its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 41.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,076 shares of the biotechnology company’s stock after selling 12,687 shares during the quarter. Portolan Capital Management LLC’s holdings in United Therapeutics were worth $7,578,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Geneos Wealth Management Inc. lifted its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the period. AE Wealth Management LLC grew its holdings in United Therapeutics by 7.6% during the 2nd quarter. AE Wealth Management LLC now owns 864 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 61 shares during the period. Allworth Financial LP grew its holdings in United Therapeutics by 147.2% during the 2nd quarter. Allworth Financial LP now owns 356 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 212 shares during the period. Police & Firemen s Retirement System of New Jersey raised its position in shares of United Therapeutics by 6.4% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 16,833 shares of the biotechnology company’s stock worth $4,837,000 after acquiring an additional 1,006 shares in the last quarter. Finally, Candriam S.C.A. raised its position in shares of United Therapeutics by 5.0% in the 2nd quarter. Candriam S.C.A. now owns 83,211 shares of the biotechnology company’s stock worth $23,912,000 after acquiring an additional 3,998 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $536.12 on Friday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $548.12. The business’s 50 day simple moving average is $486.67 and its two-hundred day simple moving average is $460.13. The firm has a market cap of $23.50 billion, a P/E ratio of 19.22, a PEG ratio of 1.92 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the company posted $6.19 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, Director Tommy G. Thompson sold 2,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $489.42, for a total transaction of $978,840.00. Following the completion of the sale, the director owned 8,480 shares in the company, valued at approximately $4,150,281.60. The trade was a 19.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $539.54, for a total transaction of $5,125,630.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $70,140.20. The trade was a 98.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 338,947 shares of company stock worth $165,516,573 in the last quarter. Insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on UTHR. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Wells Fargo & Company lifted their target price on United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. HC Wainwright increased their price target on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $548.09.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.